Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ai Lyn Tan

Showing results (91-100 of 107) with videos related to

Pageof 11
Sort By:
Rheumatology International|April 12, 2024
Collating the voice of people with autoimmune diseases: Methodology for the Third Phase of the COVAD StudiesEsha Kadam, Mahnoor Javaid, Parikshit Sen, et al.
Muscle & Nerve|July 23, 2022
COVID-19 Vaccination in Autoimmune Diseases (COVAD) study: Vaccine safety in idiopathic inflammatory myopathiesAlbert Gil-Vila, Naveen Ravichandran, Albert Selva-O'Callaghan, et al.
International Journal of Rheumatic Diseases|March 5, 2023
Pain in individuals with idiopathic inflammatory myopathies, other systemic autoimmune rheumatic diseases, and without rheumatic diseases: A report from the COVAD studySamuel Katsuyuki Shinjo, Minchul Kim, Leonardo Santos Hoff, et al.
Rheumatology International|September 5, 2023
Correlates of breakthrough COVID-19 in vaccinated patients with systemic sclerosis: survival analysis from a multicentre international patient-reported surveySakir Ahmed, Latika Gupta, Masataka Kuwana, et al.
Rheumatology International|August 14, 2022
COVAD survey 2 long-term outcomes: unmet need and protocolZoha Zahid Fazal, Parikshit Sen, Mrudula Joshi, et al.
International Journal of Rheumatic Diseases|May 14, 2024
Characteristics of emerging new autoimmune diseases after COVID-19 vaccination: A sub-study by the COVAD groupRusska Shumnalieva, Naveen Ravichandran, Jennifer Hannah, et al.
Rheumatology Advances in Practice|March 25, 2024
Impaired health-related quality of life in idiopathic inflammatory myopathies: a cross-sectional analysis from the COVAD-2 e-surveyAkira Yoshida, Yuan Li, Vahed Maroufy, et al.
Eclinicalmedicine|March 20, 2023
Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort studyHamish J C McAuley, Rachael A Evans, Charlotte E Bolton, et al.
Rheumatology International|October 22, 2022
COVID-19 severity and vaccine breakthrough infections in idiopathic inflammatory myopathies, other systemic autoimmune and inflammatory diseases, and healthy controls: a multicenter cross-sectional study from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) surveyLeonardo Santos Hoff, Naveen Ravichandran, Samuel Katsuyuki Shinjo, et al.
Rheumatology (Oxford, England)|September 26, 2024
The impact of multimorbidity on Quality of Life in inflammatory myopathies: A cluster analysis from the COVAD datasetMarco Fornaro, Vincenzo Venerito, Maria Rosa Pellico, et al.
Pageof 11

Showing results (91-100 of 107) with videos related to

Sort By:
Pageof 11
Rheumatology International|April 12, 2024
Collating the voice of people with autoimmune diseases: Methodology for the Third Phase of the COVAD StudiesEsha Kadam, Mahnoor Javaid, Parikshit Sen, et al.
Muscle & Nerve|July 23, 2022
COVID-19 Vaccination in Autoimmune Diseases (COVAD) study: Vaccine safety in idiopathic inflammatory myopathiesAlbert Gil-Vila, Naveen Ravichandran, Albert Selva-O'Callaghan, et al.
International Journal of Rheumatic Diseases|March 5, 2023
Pain in individuals with idiopathic inflammatory myopathies, other systemic autoimmune rheumatic diseases, and without rheumatic diseases: A report from the COVAD studySamuel Katsuyuki Shinjo, Minchul Kim, Leonardo Santos Hoff, et al.
Rheumatology International|September 5, 2023
Correlates of breakthrough COVID-19 in vaccinated patients with systemic sclerosis: survival analysis from a multicentre international patient-reported surveySakir Ahmed, Latika Gupta, Masataka Kuwana, et al.
Rheumatology International|August 14, 2022
COVAD survey 2 long-term outcomes: unmet need and protocolZoha Zahid Fazal, Parikshit Sen, Mrudula Joshi, et al.
International Journal of Rheumatic Diseases|May 14, 2024
Characteristics of emerging new autoimmune diseases after COVID-19 vaccination: A sub-study by the COVAD groupRusska Shumnalieva, Naveen Ravichandran, Jennifer Hannah, et al.
Rheumatology Advances in Practice|March 25, 2024
Impaired health-related quality of life in idiopathic inflammatory myopathies: a cross-sectional analysis from the COVAD-2 e-surveyAkira Yoshida, Yuan Li, Vahed Maroufy, et al.
Eclinicalmedicine|March 20, 2023
Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort studyHamish J C McAuley, Rachael A Evans, Charlotte E Bolton, et al.
Rheumatology International|October 22, 2022
COVID-19 severity and vaccine breakthrough infections in idiopathic inflammatory myopathies, other systemic autoimmune and inflammatory diseases, and healthy controls: a multicenter cross-sectional study from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) surveyLeonardo Santos Hoff, Naveen Ravichandran, Samuel Katsuyuki Shinjo, et al.
Rheumatology (Oxford, England)|September 26, 2024
The impact of multimorbidity on Quality of Life in inflammatory myopathies: A cluster analysis from the COVAD datasetMarco Fornaro, Vincenzo Venerito, Maria Rosa Pellico, et al.
Pageof 11